Pharmaceutical

Hong Kong approves Leqembi for Alzheimer’s treatment

BioArctic has announced that its partner, Eisai has approval from Hong Kong's Department of Health for Leqembi for the treatment of AD.

Jul 12, 2024 - 04:00
Hong Kong approves Leqembi for Alzheimer’s treatment
BioArctic has announced that its partner, Eisai has approval from Hong Kong's Department of Health for Leqembi for the treatment of AD.
Read the original article

Tags:

Previous Article

Biotech survey highlights where industry can focus for a thriving future  

Next Article

Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: For-profit health system’s Mass. hospitals teetering on the brink of financial disaster

STAT+: For-profit health system’s Mass. hospitals teete...

Mar 13, 2024

STAT+: Rune Labs, which makes an app to track Parkinson’s symptoms, raises $12 million

STAT+: Rune Labs, which makes an app to track Parkinson...

Jan 12, 2024

STAT+: For-profit biomedical institute, backed by billionaires, launches in Cambridge to speed drug discovery

STAT+: For-profit biomedical institute, backed by billi...

Jan 14, 2024